BlogHotel.orgAccueil | Créer un blog | Imprimer la page Imprimer | Blog hasard Au hasard | Chercher des blogs Rechercher | Entrer dans le chat du blog Chat | | Jeux Jeux | Adminitration et édition du Blog Manager

freemexy Accueil | Profil | Archives | Amis

Tamoxifen for Breast Cancer Recurrence Prevention13/8/2019
Tamoxifen for Breast Cancer Recurrence Prevention

Tamoxifen, also known by the brand name Nolvadex, is one of the more commonly prescribed medications used to prevent breast cancer recurrence. When used appropriately, it may reduce the risk of breast cancer coming back by roughly 50 percent. The drug may also be used to reduce the chance that certain women will develop breast cancer in the first place, or to slow the growth of metastatic breast cancer.Nolvadex results

Tamoxifen is a medication with both anti-estrogen and estrogen-like effects, depending on the particular type of tissue it affects. It is classified as a selective estrogen receptor modulator (SERM), along with the medication Evista (raloxifene), and considered over aromatase inhibitors (AIs) in several cases.
In women and men diagnosed with estrogen receptor-positive early-stage breast cancer after surgery, chemotherapy, and/or radiation to reduce the risk of recurrence
In women and men diagnosed with hormone receptor-positive advanced stage or metastatic breast cancer
For primary breast cancer prevention in those at an increased risk of developing the disease (a.k.a. cancer previvors)
Tamoxifen is usually not considered beneficial for those who have estrogen- or progesterone-negative breast cancer. If your cancer is estrogen receptor- as well as HER2-positive, your doctor may recommend tamoxifen (or an aromatase inhibitor), a HER2-targeted medication such as Herceptin, or both, depending on your specific situation.
Tamoxifen was approved in 1998 and has since been found effective in treating breast cancer for millions of people. It is still considered an excellent option if you are premenopausal or are postmenopausal and cannot take an aromatase inhibitor.

When used after primary treatment (e.g., surgery), it may reduce your risk of breast cancer recurrence by half if your tumor was estrogen receptor-positive. The drug continues to have this benefit even after you stop taking it.

It can also reduce your risk of developing another cancer in the same breast or a new cancer in your other breast by up to 50 percent.

In contrast to its anti-estrogen effects on breast tissue, tamoxifen has estrogen-like effects on bone. Therefore tamoxifen (as well as Evista) may help slow or stop bone loss. Tamoxifen may also lower cholesterol levels, specifically LDL cholesterol.

poster un commentaire

Article 865 of 1573
Précédent | Suivant

Blog suivant >> Signaler un abus?Haut de page
Fond écran petites annonces jeux de fille gratuit